GlaxoSmithKline (GSK) is selling its entire stake in Innoviva back to Innoviva for approximately $392 million.
Following settlement of the transaction, GSK will no longer hold any Innoviva stock.
The terms of GSK’s long-standing and successful respiratory collaboration with Innoviva remain unchanged.
Under this agreement GSK pays royalties to Innoviva on Trelegy Ellipta, Relvar/Breo Ellipta and Anoro Ellipta.
In 2020, sales of Trelegy Ellipta were £819 million; Relvar/Breo Ellipta sales were £1.1 billion, and Anoro Ellipta were £547 million.